PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer

Frontiers in Oncology

Oncology

Qiuming He¹  Zhenxian Xiang²  Tingna Chen²  Chaogang Yang²  Bin Xiong²  Jialing Song²  Zheyu Ding²  Shuyi Wang²  Haitao Wu³ 

[1] Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China;Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China;Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China;Department of Thyroid and Breast Surgery, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

关键词: PFDN2;    Cell Cycle;    MYBL2;    gastric cancer;    HNRNPD;   

DOI  :  10.3389/fonc.2023.1164070

 received in 2023-02-12, accepted in 2023-06-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

Gastric cancer (GC) is a major health burden worldwide, but our understanding of GC is limited, and the prognosis is poor. Novel therapeutic strategies and biomarkers are urgently needed to improve GC patient outcomes. Previously, we identified PFDN2 as a novel key gene in gastric cancer based on its differential expression between cancer and normal tissues. However, the role and underlying mechanisms of PFDN2 in GC remain elusive. In this article, we demonstrated that PFDN2 is highly expressed in GC and that upregulation of PFDN2 is associated with the progression of GC. We further found that PFDN2 could promote cell cycle progression by promoting MYBL2 expression. Mechanistically, we demonstrated that PFDN2 could upregulate MYBL2 expression by facilitating the nuclear translocation of hnRNPD, and thus promoting MYBL2 transcriptional program. In conclusion, we found that PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis and may serve as a potential biomarker and therapeutic target for GC.

【 授权许可】

Unknown   
Copyright © 2023 He, Ding, Chen, Wu, Song, Xiang, Yang, Wang and Xiong